Suplastast tosilate (ME-015) for the treatment of cough in idiopathic pulmonary fibrosis: Preliminary findings from the COSMIC-IPF Phase 2a trial

This randomized, placebo-controlled, Phase 2a trial will examine the safety and efficacy of suplastast tosilate (ME‑015) in ~40 patients with IPF and chronic cough. Endpoints of the trial include cough frequency, which will be measured using the Vitalograph VitaloJAK cough monitor.